Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2018-06-07 Legal Proceedings Report
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 99% confidence The document is a press release dated June 7th, 2018, announcing a clinical milestone (last patient treated in a CE marking study for varicose veins) and scheduling a web conference to discuss interim results, physician feedback, and regulatory strategy (CE & FDA filing). It discusses market potential and future regulatory steps. This content is characteristic of an announcement intended to inform investors and the market about significant operational and strategic progress, rather than a formal periodic financial report (like 10-K or IR) or a transcript. Since it is an announcement about clinical progress and upcoming regulatory strategy, it fits best under 'Regulatory Filings' (RNS) as a general corporate update, or potentially 'Capital/Financing Update' (CAP) if the context implied fundraising, but RNS is the most appropriate general category for non-standard operational news releases that don't fit ER, DIV, or MANG. Given the focus on clinical trial completion and upcoming regulatory strategy disclosure, RNS is the best fit as a general regulatory announcement.
2018-06-07 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated June 5, 2018, announcing the finalization of a clinical study for treating varicose veins using echotherapy. It details positive intermediate results, discusses regulatory strategy (CE marking and FDA submission), market potential, and invites participation in a follow-up web conference. This content—announcing clinical progress, market strategy, and upcoming regulatory steps, often associated with financial or operational updates—fits best under the 'Earnings Release' (ER) category if it were quarterly results, or potentially 'Regulatory Filings' (RNS) or 'Investor Presentation' (IP) if it were a formal presentation. However, since it is a formal announcement of significant operational/clinical progress and market outlook, and it is not a full financial report (10-K, IR) or a transcript (CT), it most closely resembles an Earnings Release (ER) which often includes operational highlights, or a general announcement. Given the focus on clinical study finalization and market potential, it functions as a key operational update. Since it is not explicitly an earnings report but a major operational update, and it is not a short announcement pointing to another document (RPA), 'ER' is the closest fit for a significant, non-mandated operational/clinical update press release, although 'RNS' is a strong secondary candidate as a general regulatory/operational announcement. FY 2018
2018-06-07 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated June 5th, 2018, announcing commercial milestones, new agreements (Diagnostikum Berlin), insurance reimbursement progress (20% of German public health insurers), and expansion of treatment applications (Frankfurt Bürgerhospital adding breast treatment). This content focuses on business development, sales achievements, and operational updates rather than formal financial reporting (like 10-K or IR), management changes (MANG), or shareholder voting (DVA). It is a general business update, which often falls under Regulatory Filings (RNS) if it's not specifically an Earnings Release (ER) or a dedicated financing announcement (CAP). Since it details operational progress and commercial agreements, RNS is the most appropriate general regulatory announcement category, as it is not a specific financial report or management disclosure.
2018-06-05 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated June 5, 2018, announcing significant commercial developments for Theraclion in the German market, specifically signing a commercial agreement with Diagnostikum Berlin for echotherapy treatments and noting increased reimbursement coverage by German public health insurers. It details business expansion, partnerships, and market potential, which is characteristic of a general business update or news release. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR), and it announces business progress rather than a specific transaction (CAP, TAR, SHA) or management change (MANG), it best fits the general category for regulatory announcements or news that doesn't fit elsewhere, which is Regulatory Filings (RNS). Given the content is a press release announcing business milestones, RNS is the most appropriate classification among the provided options.
2018-06-05 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 99% confidence The document is titled 'Assemblée générale ordinaire et extraordinaire annuelle de Theraclion' (Annual Ordinary and Extraordinary General Meeting of Theraclion) and explicitly announces that 'Toutes les résolutions agréées par le conseil d'administration ont été adoptées par les actionnaires' (All resolutions approved by the board of directors were adopted by the shareholders). It details the results of the general meeting held on May 17, 2018, including the approval of 2017 annual accounts and various corporate authorizations (share buyback, capital increases, stock options). This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2018-05-21 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 15, 2018, announcing a positive clinical outcome regarding a veterinary study using Theraclion's Echopulse device. It details research progress, market context for pet cancer therapeutics, and includes company boilerplate information and contact details. This type of announcement, focusing on a specific operational or research milestone rather than periodic financial results (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report, a transcript, or a specific corporate action notice (like dividend or share issue), the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a news update. Given the context of a company issuing news about a study outcome, RNS is the best fit as a general regulatory/news filing.
2018-05-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.